Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity. (PubMed, Front Immunol) - Sep 10, 2026 - "Traditional treatments for lung cancer include surgery, radiotherapy, chemotherapy, and targeted therapies (such as Erlotinib, Gefitinib, and Crizotinib), as well as immunotherapy (such as Nivolumab and Pembrolizumab). Against this background, this review systematically evaluates the current status and prospects of mRNA vaccines in lung cancer treatment, with a focus on their progress in precisely modulating the tumor microenvironment, identifying novel tumor antigens, discovering immune biomarkers, and related clinical studies. Additionally, the review discusses the process optimization of lipid nanoparticle (LNP) delivery systems, aiming to provide theoretical support and practical guidance for the development of safe and effective therapeutic vaccine platforms for lung cancer."
Biomarker • IO biomarker • Journal • Review • Infectious Disease • Lung Cancer • Novel Coronavirus Disease • Oncology • Solid Tumor
|
|
Chongmin Huang; Hao Wu; Jiaxuan Li; Jiyuan Wang; Keda Chen; Ruiqi Weng; Siyi Gu; Xiaotian Tie; Xiaoyan Ma
|